Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.
- DOI
- 10.1136/annrheumdis-2020-219406
- Published
- 2021 Aug
- Container
- Annals of the rheumatic diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/annrheumdis-2020-219406,
title = {Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.},
author = {Wei JC and Kim TH and Kishimoto M and Ogusu N and Jeong H and Kobayashi S and 4827-006 study group},
year = {2021},
journal = {Annals of the rheumatic diseases},
doi = {10.1136/annrheumdis-2020-219406},
url = {https://doi.org/10.1136/annrheumdis-2020-219406}
}RIS
TY - JOUR TI - Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial. AU - Wei JC AU - Kim TH AU - Kishimoto M AU - Ogusu N AU - Jeong H AU - Kobayashi S AU - 4827-006 study group PY - 2021 JO - Annals of the rheumatic diseases DO - 10.1136/annrheumdis-2020-219406 UR - https://doi.org/10.1136/annrheumdis-2020-219406 ER -
APA
JC, W., TH, K., M, K., N, O., H, J., S, K., & group, 4. S. (2021). Efficacy and safety of brodalumab, an anti-IL17RA monoclonal antibody, in patients with axial spondyloarthritis: 16-week results from a randomised, placebo-controlled, phase 3 trial.. Annals of the rheumatic diseases. https://doi.org/10.1136/annrheumdis-2020-219406
Source records
- pubmed · retrieved 2026-09-26T16:54:28.290Z